{"title":"默克公司授权Exelixis的PI3K-Delta研发项目","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I1.1649","DOIUrl":null,"url":null,"abstract":"In a potential US$251 M deal, Exelixis has granted Merck & Co. worldwide rights to its preclinical PI3K-delta R&D programme, including XL499, the programme’s lead compound that has potential in the treatment of rheumatoid arthritis, allergic asthma and haematological malignancies. Merck will be solely responsible for the research, development and commercialisation of compounds originating from the programme. The agreement will provide Exelixis with resources to continue the development of its most advanced compound, cabozantinib, which is in Phase III development for medullary thyroid cancer.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"74 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Merck & Co. Licenses Exelixis’ PI3K-Delta R&D Programme\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I1.1649\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In a potential US$251 M deal, Exelixis has granted Merck & Co. worldwide rights to its preclinical PI3K-delta R&D programme, including XL499, the programme’s lead compound that has potential in the treatment of rheumatoid arthritis, allergic asthma and haematological malignancies. Merck will be solely responsible for the research, development and commercialisation of compounds originating from the programme. The agreement will provide Exelixis with resources to continue the development of its most advanced compound, cabozantinib, which is in Phase III development for medullary thyroid cancer.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"74 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I1.1649\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I1.1649","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
In a potential US$251 M deal, Exelixis has granted Merck & Co. worldwide rights to its preclinical PI3K-delta R&D programme, including XL499, the programme’s lead compound that has potential in the treatment of rheumatoid arthritis, allergic asthma and haematological malignancies. Merck will be solely responsible for the research, development and commercialisation of compounds originating from the programme. The agreement will provide Exelixis with resources to continue the development of its most advanced compound, cabozantinib, which is in Phase III development for medullary thyroid cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
